Abrocitinib Efficacy Dose-Dependent, Similar Across AD Age Groups Abrocitinib Efficacy Dose-Dependent, Similar Across AD Age Groups

As for adverse events, nausea was more frequent in patients aged 12-17 and aged 18-40 years than it was for those age 51 or older.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news
More News: Dermatology | Skin